Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | EED | O75530 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24109716 | 0.91 | SCN9A (0.34) | TFPI2SCN9A | |
| SCHEMBL24109732 | 0.91 | SCN9A (0.34) | TFPI2SCN9A | |
| SCHEMBL24110307 | 0.90 | SCN9A (0.38) | TFPI2SCN9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24110636 | 0.90 | SCN9A (0.40) | TFPI2SCN9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25825528 | 0.87 | TFPI2 (0.37) | TFPI2SCN9ASIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL24110199 | 0.87 | TFPI2 (0.37) | TFPI2SCN9ASIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL24110299 | 0.82 | HTR2A (0.46) | TFPI2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24110041 | 0.82 | HTR2C (0.41) | TFPI2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24109857 | 0.82 | HTR2C (0.41) | TFPI2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24109866 | 0.82 | HTR2C (0.41) | TFPI2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | TFPI2 3990/4885SCN9A 3315/4885SIGMAR1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.